These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 14566216

  • 1. Effect of bupropion SR on specific symptom clusters of depression: analysis of the 31-item Hamilton Rating Scale for depression.
    Jamerson BD, Krishnan KR, Roberts J, Krishen A, Modell JG.
    Psychopharmacol Bull; 2003; 37(2):67-78. PubMed ID: 14566216
    [Abstract] [Full Text] [Related]

  • 2. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
    Hewett K, Chrzanowski W, Schmitz M, Savela A, Milanova V, Gee M, Krishen A, Millen L, Leary MO, Modell J.
    J Psychopharmacol; 2009 Jul; 23(5):531-8. PubMed ID: 18635695
    [Abstract] [Full Text] [Related]

  • 3. Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder.
    Alpert JE, Franznick DA, Hollander SB, Fava M.
    J Clin Psychiatry; 2004 Aug; 65(8):1069-75. PubMed ID: 15323591
    [Abstract] [Full Text] [Related]

  • 4. A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability.
    Thase ME, Clayton AH, Haight BR, Thompson AH, Modell JG, Johnston JA.
    J Clin Psychopharmacol; 2006 Oct; 26(5):482-8. PubMed ID: 16974189
    [Abstract] [Full Text] [Related]

  • 5. Escitalopram in the treatment of anxiety symptoms associated with depression.
    Bandelow B, Andersen HF, Dolberg OT.
    Depress Anxiety; 2007 Oct; 24(1):53-61. PubMed ID: 16937393
    [Abstract] [Full Text] [Related]

  • 6. Outcomes on the pharmacopsychometric triangle in bupropion-SR vs. buspirone augmentation of citalopram in the STAR*D trial.
    Bech P, Fava M, Trivedi MH, Wisniewski SR, Rush AJ.
    Acta Psychiatr Scand; 2012 Apr; 125(4):342-8. PubMed ID: 22077211
    [Abstract] [Full Text] [Related]

  • 7. Cognitive predictors of treatment response to bupropion and cognitive effects of bupropion in patients with major depressive disorder.
    Herrera-Guzmán I, Gudayol-Ferré E, Lira-Mandujano J, Herrera-Abarca J, Herrera-Guzmán D, Montoya-Pérez K, Guardia-Olmos J.
    Psychiatry Res; 2008 Jul 15; 160(1):72-82. PubMed ID: 18501971
    [Abstract] [Full Text] [Related]

  • 8. Double-blind, placebo-controlled evaluation of extended-release bupropion in elderly patients with major depressive disorder.
    Hewett K, Chrzanowski W, Jokinen R, Felgentreff R, Shrivastava RK, Gee MD, Wightman DS, O'Leary MC, Millen LS, Leon MC, Briggs MA, Krishen A, Modell JG.
    J Psychopharmacol; 2010 Apr 15; 24(4):521-9. PubMed ID: 19164492
    [Abstract] [Full Text] [Related]

  • 9. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression.
    Patkar AA, Masand PS, Pae CU, Peindl K, Hooper-Wood C, Mannelli P, Ciccone P.
    J Clin Psychopharmacol; 2006 Dec 15; 26(6):653-6. PubMed ID: 17110825
    [Abstract] [Full Text] [Related]

  • 10. A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia.
    Evins AE, Cather C, Culhane MA, Birnbaum A, Horowitz J, Hsieh E, Freudenreich O, Henderson DC, Schoenfeld DA, Rigotti NA, Goff DC.
    J Clin Psychopharmacol; 2007 Aug 15; 27(4):380-6. PubMed ID: 17632223
    [Abstract] [Full Text] [Related]

  • 11. Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder.
    Leuchter AF, Cook IA, Gilmer WS, Marangell LB, Burgoyne KS, Howland RH, Trivedi MH, Zisook S, Jain R, Fava M, Iosifescu D, Greenwald S.
    Psychiatry Res; 2009 Sep 30; 169(2):132-8. PubMed ID: 19709754
    [Abstract] [Full Text] [Related]

  • 12. A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients.
    Reimherr FW, Cunningham LA, Batey SR, Johnston JA, Ascher JA.
    Clin Ther; 1998 Sep 30; 20(3):505-16. PubMed ID: 9663366
    [Abstract] [Full Text] [Related]

  • 13. Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms.
    Jain AK, Kaplan RA, Gadde KM, Wadden TA, Allison DB, Brewer ER, Leadbetter RA, Richard N, Haight B, Jamerson BD, Buaron KS, Metz A.
    Obes Res; 2002 Oct 30; 10(10):1049-56. PubMed ID: 12376586
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of bupropion for relapse prevention in smokers with and without a past history of major depression.
    Cox LS, Patten CA, Niaura RS, Decker PA, Rigotti N, Sachs DP, Buist AS, Hurt RD.
    J Gen Intern Med; 2004 Aug 30; 19(8):828-34. PubMed ID: 15242467
    [Abstract] [Full Text] [Related]

  • 15. An open-label study of the effects of bupropion SR on fatigue, depression and quality of life of mixed-site cancer patients and their partners.
    Moss EL, Simpson JS, Pelletier G, Forsyth P.
    Psychooncology; 2006 Mar 30; 15(3):259-67. PubMed ID: 16041840
    [Abstract] [Full Text] [Related]

  • 16. Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine.
    Baldwin D, Bridgman K, Buis C.
    J Psychopharmacol; 2006 Jan 30; 20(1):91-6. PubMed ID: 16204325
    [Abstract] [Full Text] [Related]

  • 17. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I.
    Eur Neuropsychopharmacol; 2004 Dec 30; 14(6):457-70. PubMed ID: 15589385
    [Abstract] [Full Text] [Related]

  • 18. A comparative, randomized, double-blind study of trazodone prolonged-release and sertraline in the treatment of major depressive disorder.
    Munizza C, Olivieri L, Di Loreto G, Dionisio P.
    Curr Med Res Opin; 2006 Sep 30; 22(9):1703-13. PubMed ID: 16968574
    [Abstract] [Full Text] [Related]

  • 19. A comparative study of the efficacy and safety profiles between fluvoxamine and nortriptyline in Japanese patients with major depression.
    Otsubo T, Akimoto Y, Yamada H, Koda R, Aoyama H, Tanaka K, Mimura M, Nakagome K, Kamijima K.
    Pharmacopsychiatry; 2005 Jan 30; 38(1):30-5. PubMed ID: 15706464
    [Abstract] [Full Text] [Related]

  • 20. Difference in pre- and post-treatment plasma DHEA levels were significantly and positively correlated with difference in pre- and post-treatment Hamilton depression scores following successful therapy for major depression.
    Hsiao CC.
    Psychoneuroendocrinology; 2006 Aug 30; 31(7):839-46. PubMed ID: 16716529
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.